#296 A mid-study update on the ACTION3 pivotal Phase 3 trial assessing DMX-200 in patients with focal segmental glomerulosclerosis (FSGS)
Sign Up to like & getrecommendations! Published in 2025 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaf116.0253
Abstract: Focal segmental glomerulosclerosis (FSGS) is a major cause of glomerular disease that can rapidly progress to end-stage kidney disease. Lack of safe and effective treatment represents a significant unmet need for patients with FSGS. Development… read more here.
Keywords: disease; action3; dmx 200; fsgs ... See more keywords